• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

皮肤鳞状细胞癌中尿激酶型纤溶酶原激活物受体mRNA的癌细胞表达

Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.

作者信息

Rømer J, Pyke C, Lund L R, Ralfkiaer E, Danø K

机构信息

The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.

出版信息

J Invest Dermatol. 2001 Mar;116(3):353-8. doi: 10.1046/j.1523-1747.2001.01241.x.

DOI:10.1046/j.1523-1747.2001.01241.x
PMID:11231307
Abstract

In this study we have used in situ hybridization with radiolabeled antisense RNA probes to examine the expression of mRNA for urokinase-type plasminogen activator and its receptor in histologic samples of squamous cell (n = 7) and basal cell (n = 7) carcinomas of the skin. Messenger RNA for both urokinase-type plasminogen activator and its receptor were expressed in all of the squamous cell carcinomas, but could not be detected in the basal cell carcinomas. In all of the seven squamous cell carcinomas a signal for urokinase-type plasminogen activator receptor mRNA was detected focally in well-differentiated cancer cells surrounding keratinized pearls, and in four specimens urokinase-type plasminogen activator receptor mRNA was in addition expressed by cancer cells at the edge of invasively growing strands of tumor. Urokinase-type plasminogen activator mRNA expression was found in virtually all the cancer cells of the squamous cell carcinomas, and importantly we found, by hybridizations for urokinase-type plasminogen activator and its receptor mRNA on adjacent sections of squamous cell carcinomas, that it was exactly the invading cancer cells that simultaneously expressed both these components required for plasmin-mediated proteolysis at the cell surface. We have previously shown that both urokinase-type plasminogen activator and its receptor mRNA are expressed by the leading-edge keratinocytes in regenerating epidermis during mouse skin wound healing, and that wound healing is impaired in mice made deficient in plasminogen by targeted gene disruption. We propose that there are similarities between the mechanisms of generation and regulation of extracellular proteolysis during skin re-epithelialization and squamous cell carcinoma invasion. The ability of the squamous carcinoma cells to mimic the "invasive" phenotype of re-epithelializing keratinocytes may be one of the factors that make squamous cell carcinomas more aggressive tumors than basal cell carcinomas.

摘要

在本研究中,我们使用放射性标记的反义RNA探针进行原位杂交,以检测尿激酶型纤溶酶原激活剂及其受体的mRNA在皮肤鳞状细胞癌(n = 7)和基底细胞癌(n = 7)组织学样本中的表达。尿激酶型纤溶酶原激活剂及其受体的信使RNA在所有鳞状细胞癌中均有表达,但在基底细胞癌中未检测到。在所有7例鳞状细胞癌中,在角质化珠周围分化良好的癌细胞中局部检测到尿激酶型纤溶酶原激活剂受体mRNA信号,并且在4个标本中,侵袭性生长的肿瘤条索边缘的癌细胞也表达尿激酶型纤溶酶原激活剂受体mRNA。尿激酶型纤溶酶原激活剂mRNA表达几乎在鳞状细胞癌的所有癌细胞中均有发现,重要的是,我们通过在鳞状细胞癌相邻切片上对尿激酶型纤溶酶原激活剂及其受体mRNA进行杂交发现,正是侵袭性癌细胞同时表达了细胞表面纤溶酶介导的蛋白水解所需的这两种成分。我们先前已经表明,在小鼠皮肤伤口愈合过程中,尿激酶型纤溶酶原激活剂及其受体mRNA在再生表皮的前沿角质形成细胞中表达,并且通过靶向基因破坏使纤溶酶原缺乏的小鼠伤口愈合受损。我们提出,在皮肤再上皮化和鳞状细胞癌侵袭过程中,细胞外蛋白水解的产生和调节机制之间存在相似性。鳞状癌细胞模拟再上皮化角质形成细胞“侵袭性”表型的能力可能是使鳞状细胞癌比基底细胞癌更具侵袭性肿瘤的因素之一。

相似文献

1
Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.皮肤鳞状细胞癌中尿激酶型纤溶酶原激活物受体mRNA的癌细胞表达
J Invest Dermatol. 2001 Mar;116(3):353-8. doi: 10.1046/j.1523-1747.2001.01241.x.
2
The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds.在小鼠皮肤伤口再上皮化过程中,尿激酶型纤溶酶原激活剂受体由前沿的角质形成细胞表达。
J Invest Dermatol. 1994 Apr;102(4):519-22. doi: 10.1111/1523-1747.ep12373187.
3
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.尿激酶型纤溶酶原激活物及其受体和纤溶酶原激活物抑制剂-2在食管鳞状细胞癌中的细胞分布及临床价值
Am J Pathol. 2000 Feb;156(2):567-75. doi: 10.1016/S0002-9440(10)64761-X.
4
UVB increases urokinase-type plasminogen activator receptor (uPAR) expression.
J Invest Dermatol. 1999 Jul;113(1):69-76. doi: 10.1046/j.1523-1747.1999.00631.x.
5
Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.尿激酶型纤溶酶原激活物、纤溶酶原激活物受体及纤溶酶原激活物抑制剂-2在正常人体子宫内膜和子宫内膜癌中的mRNA差异表达
Gynecol Oncol. 2000 Nov;79(2):244-50. doi: 10.1006/gyno.2000.5959.
6
Retinoic acid upregulates the plasminogen activator system in human epidermal keratinocytes.维甲酸上调人表皮角质形成细胞中的纤溶酶原激活物系统。
J Invest Dermatol. 2001 May;116(5):778-84. doi: 10.1046/j.1523-1747.2001.01310.x.
7
Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion.异种移植侵袭过程中肿瘤细胞和基质细胞对尿激酶型纤溶酶原激活物及其受体的表达。
Int J Cancer. 1994 May 15;57(4):553-60. doi: 10.1002/ijc.2910570419.
8
Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Clin Cancer Res. 1998 Apr;4(4):869-77.
9
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.层粘连蛋白-5是某些人类癌症中侵袭性癌细胞的标志物,并且在结肠腺癌的萌芽癌细胞中与尿激酶型纤溶酶原激活物受体共表达。
Cancer Res. 1995 Sep 15;55(18):4132-9.
10
Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: analysis by Northern blotting and in situ hybridization.尿激酶型纤溶酶原激活剂、其受体及抑制剂的mRNA在人非小细胞肺癌组织中过表达:Northern印迹法和原位杂交分析
Int J Cancer. 1998 Oct 29;78(3):286-92. doi: 10.1002/(SICI)1097-0215(19981029)78:3<286::AID-IJC4>3.0.CO;2-R.

引用本文的文献

1
Extracellular matrix in skin diseases: The road to new therapies.皮肤疾病中的细胞外基质:通向新疗法的道路。
J Adv Res. 2023 Sep;51:149-160. doi: 10.1016/j.jare.2022.11.008. Epub 2022 Dec 5.
2
Cancer Progression Gene Expression Profiling Identifies the Urokinase Plasminogen Activator Receptor as a Biomarker of Metastasis in Cutaneous Squamous Cell Carcinoma.癌症进展基因表达谱分析确定尿激酶型纤溶酶原激活物受体为皮肤鳞状细胞癌转移的生物标志物。
Front Oncol. 2022 Apr 11;12:835929. doi: 10.3389/fonc.2022.835929. eCollection 2022.
3
The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets.
尿激酶型纤溶酶原激活系统在胰腺癌中的作用:有前景的诊断和治疗靶点。
Biomolecules. 2022 Jan 18;12(2):152. doi: 10.3390/biom12020152.
4
The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.尿激酶受体(uPAR)作为靶向癌症治疗中的“特洛伊木马”:挑战与机遇
Cancers (Basel). 2021 Oct 27;13(21):5376. doi: 10.3390/cancers13215376.
5
Markers of Cancer Cell Invasion: Are They Good Enough?癌细胞侵袭的标志物:它们足够好吗?
J Clin Med. 2019 Jul 24;8(8):1092. doi: 10.3390/jcm8081092.
6
Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.转化生长因子-β与尿激酶型纤溶酶原激活剂:肿瘤发生中的危险组合——对皮肤癌的影响
ISRN Dermatol. 2013 Jul 18;2013:597927. doi: 10.1155/2013/597927. eCollection 2013.
7
Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin.通过全身给予双重 uPA 和 MMP 激活的工程炭疽毒素靶向头颈部鳞状细胞癌。
PLoS One. 2011;6(5):e20532. doi: 10.1371/journal.pone.0020532. Epub 2011 May 31.
8
A deficiency of uPAR alters endothelial angiogenic function and cell morphology.尿激酶型纤溶酶原激活物受体(uPAR)缺乏会改变内皮细胞的血管生成功能和细胞形态。
Vasc Cell. 2011 May 2;3(1):10. doi: 10.1186/2045-824X-3-10.
9
Phenotypic overlap between MMP-13 and the plasminogen activation system during wound healing in mice.在小鼠伤口愈合过程中,MMP-13 与纤溶酶原激活系统之间存在表型重叠。
PLoS One. 2011 Feb 4;6(2):e16954. doi: 10.1371/journal.pone.0016954.
10
A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.在尿激酶受体表达时,玻连蛋白和尿激酶在调节细胞形态方面的复合作用。
J Biol Chem. 2008 May 30;283(22):15217-23. doi: 10.1074/jbc.C700214200. Epub 2008 Mar 24.